Filing Flows

Filing Flows › 8-K events › Perspective Therapeutics

Perspective Therapeutics: results of operations

Form 8-K filed Nov 9, 2026 · items 2.02, 8.01

FDA decisionsPerspective Therapeutics Provides Recent Business Highlights and

What the filing says

• Updated interim data from the Phase 1/2a bamzireotide navoxetan (VMT-α-NET) presentations continue to support an emerging therapeutic window and potential to achieve a best-in-class profile in NETs • Meaningful antitumor activity observed for lapemelanotide zapixetar (VMT01) monotherapy in metastatic melanoma to be e

Read the filing on SEC EDGAR →

What usually followsAcross 69,249 8-Ks reporting Item 2.02 (results of operations) in our universe, the stock's median move the next session was +0.2% (typical size ±3.6%, up 51% of the time); over the following 21 sessions, +1.2%. Item 8.01: +0.1% next session across 44,918. Every item ranked →

Other recent fda decisions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.